Us Bancorp \De\ Verona Pharma PLC Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Verona Pharma PLC stock. As of the latest transaction made, Us Bancorp \De\ holds 8,627 shares of VRNA stock, worth $532,027. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,627

Previous 21,955 60.71%

Holding current value

$532,027

Previous $631,000 36.61%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	SELL	$28.71 - $47.02 $382,646 - $626,682	-13,328 Reduced 60.71%	8,627 $400,000
Q3 2024 Oct 28, 2024	SELL	$15.46 - $30.16 $30,610 - $59,716	-1,980 Reduced 8.27%	21,955 $631,000
Q2 2024 Aug 06, 2024	BUY	$11.48 - $17.02 $1,297 - $1,923	113 Added 0.47%	23,935 $346,000
Q1 2024 May 07, 2024	SELL	$15.3 - $20.24 $279,684 - $369,987	-18,280 Reduced 43.42%	23,822 $383,000
Q4 2023 Feb 09, 2024	SELL	$11.94 - $20.47 $153,142 - $262,548	-12,826 Reduced 23.35%	42,102 $836,000
Q3 2023 Nov 03, 2023	SELL	$16.3 - $22.09 $128,721 - $174,444	-7,897 Reduced 12.57%	54,928 $895,000
Q2 2023 Aug 09, 2023	SELL	$19.41 - $23.43 $137,345 - $165,790	-7,076 Reduced 10.12%	62,825 $1.33 Million
Q1 2023 May 09, 2023	BUY	$18.06 - $25.27 $363,890 - $509,165	20,149 Added 40.5%	69,901 $1.4 Million
Q4 2022 Feb 13, 2023	BUY	$9.84 - $26.13 $35,984 - $95,557	3,657 Added 7.93%	49,752 $1.3 Million
Q3 2022 Oct 27, 2022	BUY	$4.14 - $13.59 $174,935 - $574,245	42,255 Added 1100.39%	46,095 $471,000
Q1 2018 May 08, 2018	BUY	$11.69 - $20.97 $44,889 - $80,524	3,840 New	3,840 $77,000

Others Institutions Holding VRNA

# of Institutions

189

Shares Held

68.6M

Call Options Held

746K

Put Options Held

687K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $3.76B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account